Skip to content
All Podcasts – Lifestyle
Author:
Thryv Therapeutics Inc.
Thryv Therapeutics to Participate in the UBS Global Biopharma Conference in London
November 12, 2026
Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT Syndrome
November 3, 2026
Thryv Therapeutics Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure
September 15, 2026
Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain’s CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease
September 3, 2026
NetworkNews Audio Announces Audio Press Release (APR) Discussing Rebuilding of Defense Space, Power of Exclusive Rights to Proprietary Platform
August 31, 2026
NetworkNews Audio Announces Audio Press Release (APR) Discussing Ambitious Effort to Develop Energy Platform to Meet Future Demand
July 10, 2026